Dosing and uses of Ontinua ER (arbaclofen)
Spasticity
Pending FDA approval for treatment of spasticity in patients with multiple sclerosis (MS)
Pharmacology of Ontinua ER (arbaclofen)
Mechanism of action
Prodrug that is converted R-enantiomer of baclofen; allows for oral dosing with higher bioavailability
Inhibits synaptic transmission through spinal reflex arcs via hyperpolarization of primary afferent fiber terminals; this inhibition may decrease in muscle spasticity
